**GORE® VIABAHN®**
Endoprosthesis
with PROPATEN Bioactive Surface*

# PROVEN PATENCY.† DEMONSTRATED DURABILITY.†

## Gore Japan Post-Market Clinical Study

* As used by Gore, PROPATEN Bioactive Surface refers to Gore's proprietary CBAS® Heparin Surface.

† GORE® VIABAHN® Endoprosthesis. W. L. Gore & Associates website. Accessed October 24, 2023. https://www.goremedical.com/VIABAHN/references.

*Together, improving life*

# Gore Japan Post-Market Clinical Study results: Durable clinical outcomes through 5 years

## Complex, real-world patient population with challenging superficial femoral artery (SFA) disease[1]:

- 24 cm average lesion length
- 70% chronic total occlusions (CTO)
- 27% critical limb-threatening ischemia (CLTI)
- 48% TASC II D lesions

## Proven patency

85% primary patency at 1 year, 62% at 5 years[2]




Multivariate analyses did not reveal differences in primary patency for risk factors including lesion length, TASC II class, calcification or CLTI.[2]

## Demonstrated durability

92.4% freedom from target lesion revascularization (fTLR) at 1 year, 75.9% at 5 years[2]




No acute limb ischemia or stent fractures through 5 years.[2]

* Weighted average lesion length. † One-year weighted average primary patency. ‡ CTO percentage defined as percentage of TASC II D.

## Proven patency at 1 year in complex SFA lesions across 7 multicenter, prospective, randomized or single-arm studies[2–8]

**1,089**
lesions studied

**71%**
chronic total occlusions (CTO)

**23 cm**
average lesion length*

**80%**
average primary patency†

| Trial name | Number of lesions | Mean lesion length (cm) | CTOs (%) | 1-year primary patency (%) | 1-year secondary patency (%) |
|---|---|---|---|---|---|
| SuperB Study[3] | 63 | 23 | 75‡ | 65 | 86 |
| Gore VIPER Clinical Study[4] | 119 | 19 | 56 | 73 | 92 |
| VIASTAR Trial[5] | 66 | 19 | 79 | 78 | 90 |
| 25 cm Trial[6] | 71 | 27 | 93 | 67 | 97 |
| Gore Japan IDE Clinical Study[7] | 103 | 22 | 66 | 88 | 98 |
| **Gore Japan Post-Market Clinical Study[2]** | **324** | **24** | **70** | **85** | **95** |
| VANQUISH Study[8] | 343 | 25 | 71 | 80 | N/A |
| **Combined results (Weighted average, as appropriate)** | **1,089** | **23** | **71** | **80** | **94** |

## References


1. Iida O, Ohki T, Soga Y, *et al.* Twelve-month outcomes from the Japanese post-market surveillance study of the Viabahn Endoprosthesis as treatment for symptomatic peripheral arterial disease in the superficial femoral arteries. *Journal of Endovascular Therapy* 2022;29(6):855-865. https://journals.sagepub.com/doi/full/10.1177/15266028211067739
2. Iida O. 5-year outcomes of the Gore® Viabahn® Endoprosthesis for the treatment of complex femoropopliteal lesions in a Japanese population. Presented at the 21st Annual Vascular InterVentional Advances (VIVA); October 30, 2023-November 2, 2023; Las Vegas, NV.
3. Reijnen MMPJ, van Walraven LA, Fritschy WM, *et al.* 1-year results of a multicenter randomized controlled trial comparing heparin-bonded endoluminal to femoropopliteal bypass. *JACC: Cardiovascular Interventions* 2017;10(22):2320-2331. http://www.sciencedirect.com/science/article/pii/S1936879817319775
4. Saxon RR, Chervu A, Jones PA, *et al.* Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) Trial. *Journal of Vascular & Interventional Radiology* 2013;24(2):165-173.
5. Lammer J, Zeller T, Hausegger KA, *et al.* Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). *Journal of the American College of Cardiology* 2013;62(15):1320-1327.
6. Zeller T, Peeters P, Bosiers M, *et al.* Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm Trial. *Journal of Endovascular Therapy* 2014;21(6):765-774.
7. Ohki T, Kichikawa K, Yokoi H, *et al.* Long-term results of the Japanese multicenter Viabahn trial of heparin bonded endovascular stent grafts for long and complex lesions in the superficial femoral artery. *Journal of Vascular Surgery* 2021;74(6):1958-1967.e2. https://www.sciencedirect.com/science/article/pii/S0741521421010119
8. Iida O, Takahara M, Soga Y, *et al*; VANQUISH Investigators. One-year outcomes of heparin-bonded stent-graft therapy for real-world femoropopliteal lesions and the association of patency with the prothrombotic state based on the prospective, observational, multicenter *Via*bahn Ste*n*t-Graft Placement for Femoropopliteal Diseases Re*qui*ring Endovas*c*ular T*h*erapy (VANQUISH) Study. *Journal of Endovascular Therapy* 2021;28(1):123-131.


Consult Instructions for Use
**eifu.goremedical.com**

Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the market where this product is available. ℞ Only

Products listed may not be available in all markets.




**W. L. Gore & Associates, Inc.**
goremedical.com

**Asia Pacific** +65 6733 2882 **Australia/New Zealand** 1800 680 424 **Europe** 00800 6334 4673
**United States** Flagstaff, AZ 86004 800 437 8181 928 779 2771